Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1349P - Application of a classifier combining bronchial transcriptomics and chest CT features facilitates the diagnostic evaluation of lung cancer in smokers and non-smokers

Date

16 Sep 2021

Session

ePoster Display

Topics

Staging and Imaging

Tumour Site

Thoracic Malignancies

Presenters

Wen Li

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

W. Li1, Y. Xia2, S. Ying1, R. Jin1, H. Wu3, Y. Shen4, T. Yin4, F. Yan1, W. Zhang4, F. Lan1, B. Zhang1, C. Zhu1, C. Li3, H. Shen1

Author affiliations

  • 1 88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, 310009 - Hangzhou/CN
  • 2 Department Of Respiratory And Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, 310009 - Hangzhou/CN
  • 3 Department Of Human Genetics, Zhejiang University School of Medicine, 310009 - Hangzhou/CN
  • 4 Hangzhou Mitigenomics Technology Co., Hangzhou Mitigenomics Technology Co., Hangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1349P

Background

Lung cancer screening by computed tomography (CT) reduces mortality but exhibited high false-positive rates. We established a diagnostic classifier combining chest CT features with bronchial transcriptomics.

Methods

Patients with CT-detected suspected lung cancer were enrolled. The sample collected by bronchial brushing was used for RNA sequencing. The e1071 and pROC packages in R software was applied to build the model.

Results

Eventually, a total of 283 patients, including 183 with lung cancer and 100 with benign lesions, were included into final analysis. When incorporating transcriptomic data with radiological characteristics, the advanced model yielded 0.903 AUC with 81.1% NPV. Moreover, the classifier performed well regardless of lesion size, location, stage, histologic type, or smoking status. Pathway analysis showed enhanced epithelial differentiation, tumor metastasis, and impaired immunity were predominant in smokers with cancer, whereas tumorigenesis played a central role in non-smokers with cancer. Apoptosis and oxidative stress contributed critically in metastatic lung cancer; by contrast, immune dysfunction was pivotal in locally advanced lung cancer.

Conclusions

Collectively, we devised a minimal-to-noninvasive, efficient diagnostic classifier for smokers and non-smokers with lung cancer, which provides evidence for different mechanisms of cancer development and metastasis associated with smoking. A negative classifier result will help the physician make conservative diagnostic decisions.

Clinical trial identification

ChiCTR-DPD-17011856.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

National Natural Science Foundation of China [81870022]; Zhejiang Provincial Natural Science Foundation [LY20H010004].

Disclosure

Y. Shen, T. Yin, W. Zhang: Financial Interests, Institutional, Full or part-time Employment: Mitigenomics Technology Co. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.